KEGG   DRUG: Apadamtase alfa and cinaxadamtase alfa
Entry
D12835            Mixture   Drug                                   
Name
Apadamtase alfa and cinaxadamtase alfa;
Recombinant ADAMTS13;
Apadamtase alfa (genetical recombination) and cinaxadamtase alfa (genetical recombination);
ADAMTS13, recombinant-krhn;
Adzynma (TN)
Product
ADZYNMA (TAKEDA PHARMACEUTICALS AMERICA)
Component
Apadamtase alfa [DR:D12569], Cinaxadamtase alfa [DR:D12570]
Remark
Therapeutic category: 3399
ATC code: B01AD13
Product: D12835<JP/US>
Efficacy
Antithrombotic
  Disease
Congenital thrombotic thrombocytopenic purpura [DS:H00225]
  Type
Enzyme replacement therapy product
Comment
Purified bivariant human recombinant ADAMTS13 (rADAMTS13). (a mixture of native rADAMTS13 Q23 and Variant rADAMTS13 R23)
Target
ADAMTS13 [HSA:11093] [KO:K08627]
  Pathway
hsa04611  Platelet activation
  Network
nt06514  Coagulation cascade
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B01 ANTITHROMBOTIC AGENTS
   B01A ANTITHROMBOTIC AGENTS
    B01AD Enzymes
     B01AD13 Apadamtase alfa and cinaxadamtase alfa
      D12835  Apadamtase alfa and cinaxadamtase alfa <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  33  Blood and body fluid agents
   339  Miscellaneous
    3399  Others
     D12835  Apadamtase alfa and cinaxadamtase alfa
Target-based classification of drugs [BR:br08310]
 Peptidases and inhibitors
  Metallo peptidases
   Family M12
    ADAMTS13
     D12835  Apadamtase alfa and cinaxadamtase alfa <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12835
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12835
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D12835
Other DBs
PubChem: 497621248
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system